Literature DB >> 28606241

[Effects of recombinant fusion protein interleukin-18 on expression of immune-inflammatory factors in mice infected with Staphylococcus aureus].

Chen Chen1, Qiang Chen, Lan Li, Xiao-Jun Yu, Jiang-Wei Ke, Mei-Juan He, Hong-Ping Zhou, Wen-Ping Yang, Wen-Xing Wang.   

Abstract

OBJECTIVE: To observe the effects of recombinant fusion protein interleukin (IL)-18 on the expression of immune-inflammatory factors in the mice infected with Staphylococcus aureus (SA), and to investigate the mechanism of action of IL-18 in defense of SA infection in vivo.
METHODS: A total of 40 specific pathogen-free female BLAB/c mice were randomly divided into four groups: control, SA infection, immunized, and intervention. A mouse model of SA infection was established by nasal inoculation with SA liquid. The immunized group and the intervention group were intranasally given IL-18 before SA modeling, and then the SA infection group and the intervention group received the nasal inoculation with SA liquid; the control group was treated with phosphate buffered saline instead. The levels of IL-4, interferon (IFN)-γ, tumor necrosis factor (TNF), granulocyte colony-stimulating factor (G-CSF), IgM in the serum and bronchoalveolar lavage fluid (BALF) of mice were measured by enzyme-linked immunosorbent assay. The expression of macrophage inflammatory protein (MIP)-1α mRNA and MIP-2β mRNA in the lung tissue of mice were determined by real-time fluorescent quantitative PCR.
RESULTS: Compared with the control group, the SA infection group and the immunized group had significantly higher levels of IL-4, G-CSF, and IgM in the serum and BALF and expression of MIP-1α mRNA and MIP-2β mRNA in the lung tissue (P<0.05); the SA infection group had a significantly lower level of IFN-γ and a significantly higher level of TNF in the serum and BALF (P<0.05); the immunized group had a significantly higher level of IFN-γ in the serum and BALF (P<0.05). Compared with the SA infection group, the intervention group had significantly higher levels of IL-4, IFN-γ, G-CSF, and IgM in the serum and BALF and expression of MIP-1α mRNA in the lung tissue. In contrast, the intervention group showed a significantly lower level of TNF in the serum and BALF and expression of MIP-2β mRNA in the lung tissue (P<0.05). All the above indicators in the intervention group were significantly higher than those in the control group (P<0.05), except the serum level of IFN-γ.
CONCLUSIONS: In the mice infected with SA, the recombinant fusion protein IL-18 by mucosal immunity can affect inflammatory factors in the serum and BALF and the expression of MIP-1α mRNA and MIP-2β mRNA in the lung tissue to promote the anti-infective immune response and enhance the ability to clear pathogens.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28606241      PMCID: PMC7390305     

Source DB:  PubMed          Journal:  Zhongguo Dang Dai Er Ke Za Zhi        ISSN: 1008-8830


  31 in total

Review 1.  The pathophysiology and treatment of sepsis.

Authors:  Richard S Hotchkiss; Irene E Karl
Journal:  N Engl J Med       Date:  2003-01-09       Impact factor: 91.245

2.  Staphylococcus aureus protein A induces airway epithelial inflammatory responses by activating TNFR1.

Authors:  Marisa I Gómez; Aram Lee; Bharat Reddy; Amanda Muir; Grace Soong; Allyson Pitt; Ambrose Cheung; Alice Prince
Journal:  Nat Med       Date:  2004-07-11       Impact factor: 53.440

3.  The inflammatory cytokine IL-18 induces self-reactive innate antibody responses regulated by natural killer T cells.

Authors:  Sara Lind Enoksson; Emilie K Grasset; Thomas Hägglöf; Nina Mattsson; Ylva Kaiser; Susanne Gabrielsson; Tracy L McGaha; Annika Scheynius; Mikael C I Karlsson
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-01       Impact factor: 11.205

4.  Microbiological and inflammatory factors associated with the development of pneumococcal pneumonia.

Authors:  F Dallaire; N Ouellet; Y Bergeron; V Turmel; M C Gauthier; M Simard; M G Bergeron
Journal:  J Infect Dis       Date:  2001-06-26       Impact factor: 5.226

Review 5.  Neutralization of tumor necrosis factor in preclinical models of sepsis.

Authors:  José A Lorente; John C Marshall
Journal:  Shock       Date:  2005-12       Impact factor: 3.454

6.  Effect of protein A on staphylococcal opsonization.

Authors:  P K Peterson; J Verhoef; L D Sabath; P G Quie
Journal:  Infect Immun       Date:  1977-03       Impact factor: 3.441

Review 7.  The role of nasal carriage in Staphylococcus aureus infections.

Authors:  Heiman F L Wertheim; Damian C Melles; Margreet C Vos; Willem van Leeuwen; Alex van Belkum; Henri A Verbrugh; Jan L Nouwen
Journal:  Lancet Infect Dis       Date:  2005-12       Impact factor: 25.071

8.  In vivo gene silencing (with siRNA) of pulmonary expression of MIP-2 versus KC results in divergent effects on hemorrhage-induced, neutrophil-mediated septic acute lung injury.

Authors:  Joanne L Lomas-Neira; Chun-Shiang Chung; Doreen E Wesche; Mario Perl; Alfred Ayala
Journal:  J Leukoc Biol       Date:  2005-02-04       Impact factor: 4.962

9.  Staphylococcus aureus synthesizes adenosine to escape host immune responses.

Authors:  Vilasack Thammavongsa; Justin W Kern; Dominique M Missiakas; Olaf Schneewind
Journal:  J Exp Med       Date:  2009-09-28       Impact factor: 14.307

10.  Chemotaxis inhibitory protein of Staphylococcus aureus, a bacterial antiinflammatory agent.

Authors:  Carla J C de Haas; Karin Ellen Veldkamp; Andreas Peschel; Floor Weerkamp; Willem J B Van Wamel; Erik C J M Heezius; Miriam J J G Poppelier; Kok P M Van Kessel; Jos A G van Strijp
Journal:  J Exp Med       Date:  2004-03-01       Impact factor: 14.307

View more
  1 in total

1.  The Antioxidant Polysaccharide from Semiaquilegia adoxoides (DC.) Makino Adjusts the Immune Response of Mice Infected by Bacteria.

Authors:  Yunqiao Yang; Lei Guo; Kinza Tariq; Weiyu Zhang; Chong Li; Fareed Qamar Memon; Beibei Chai; Zheng Li; Junying Sun; Yunru Chen; Geyin Zhang; Qinmei Li; Shuaiyang Wang; Lizhen Wang; Chongbo Lai; Mingsheng Jiang; Hongbin Si
Journal:  Evid Based Complement Alternat Med       Date:  2020-02-19       Impact factor: 2.629

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.